circadian clock raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-10 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Reception == The review aggregator website Rotten Tomatoes reports a 95% approval rating with an average rating of 7.80/10 based on 20 reviews. The website's consensus reads, "Increased pressure on a key couple brings heightened stakes and more exciting twists to Scandal's action-packed, consistently gripping fifth season.
1956: The association "La Maternité Heureuse," which would become the French Movement for Family Planning (MFPF) in 1960, is founded; its goals include sex education and advocacy for the right to contraception and abortion. December 11, 1956: Law on the housewife allowance, extended beyond agricultural professions. March 25, 1957: Treaty of Rome establishing the European Economic Community; it includes a principle of equal pay for men and women for identical work.
Suckling lamb or milk-fed lamb Meat from an unweaned lamb, typically 4–6 weeks old and weighing 5.5–8 kg; this is typically unavailable in the United States and the United Kingdom. The flavour and texture of milk-fed lamb when grilled (such as the small lamb cutlets known as chuletillas in Spain) or roasted (lechazo asado or cordero lechal asado) is generally thought to be finer than that of older lamb, and fetches higher prices. The areas in northern Spain where this can be found include Asturias, Cantabria, Castile and León, and La Rioja. Milk-fed lambs are especially prized for Easter in Greece, when they are roasted on a spit. Young lamb A milk-fed lamb between six and eight weeks old Spring lamb A lamb, usually three to five months old, born in late winter or early spring and sold usually before 1 July (in the northern hemisphere). Sucker lambs A term used in Australia — includes young milk-fed lambs, as well as slightly older lambs up to about seven months of age which are also still dependent on their mothers for milk. Carcasses from these lambs usually weigh between 14 and 30 kg. Older weaned lambs which have not yet matured to become mutton are known as old-season lambs.
=== Shared care === Shared decision making is an approach whereby patients and clinicians freely share important evidence when tasked with decision making and where patients are guided to consider the best available options to make an informed decision. The principles are well documented, but there is a gap in that it's hard to apply them in routine clinical practice. The steps have been simplified into five steps. The first step is seeking patient participation in that the health practitioner is tasked with communicating existing choices and therefore inviting them to the decision-making process. The next step involves assisting the patient to explore and compare the treatment options by a critical analysis of the risks and benefits. The third step involves the assessment of the patient's values and what they prefer taking to account what is of paramount urgency to the patient. Step 4 involves decision making where the patient and the practitioner make a conclusive decision on the best option and arrange for subsequent follow up meetings. Finally, the fifth step involves the analysis of the patient's decision'. Five steps for you and your patients to work together to make the best possible health care decisions. The step involves monitoring of the degree of implementation, overcoming of barriers of decision implantation consequently the decisions need to be revisited and optimized thus ensuring the decision has a positive impact on health outcomes. Its success relies on the ability of the health practitioner to create a good interpersonal relationship with the patient.
A number of people, starting with Gerald Kulcinski in 1986, have proposed to explore the Moon, mine lunar regolith, and use the helium-3 for fusion. Liquid helium-4 can be cooled to about 1 K (−272.15 °C; −457.87 °F) using evaporative cooling in a 1-K pot. Similar cooling of helium-3, which has a lower boiling point, can achieve about 0.2 kelvin in a helium-3 refrigerator. Equal mixtures of liquid 3He and 4He below 0.8 K separate into two immiscible phases due to their dissimilarity (they follow different quantum statistics: helium-4 atoms are bosons while helium-3 atoms are fermions). Dilution refrigerators use this immiscibility to achieve temperatures of a few millikelvins. It is possible to produce exotic helium isotopes, which rapidly decay into other substances. The shortest-lived heavy helium isotope is the unbound helium-10 with a half-life of 2.6(4)×10−22 s. Helium-6 decays by emitting a beta particle and has a half-life of 0.8 seconds. Helium-7 and helium-8 are created in certain nuclear reactions. Helium-6 and helium-8 are known to exhibit a nuclear halo.
Sources: en.wikipedia.org
=== Sunblock and sunscreen === Sunblock and sunscreen are different important skin-care products though both offer full protection from the sun. Sunblock—Sunblock is opaque and stronger than sunscreen, since it is able to block most of the UVA/UVB rays and radiation from the sun, and does not need to be reapplied several times in a day. Titanium dioxide and zinc oxide are two of the important ingredients in sunblock. Sunscreen—Sunscreen is more transparent once applied to the skin and also has the ability to protect against UVA/UVB rays, although the sunscreen's ingredients have the ability to break down at a faster rate once exposed to sunlight, and some of the radiation is able to penetrate to the skin. In order for sunscreen to be more effective it is necessary to consistently reapply and use one with a higher sun protection factor.
Rates of MI for a given age have decreased globally between 1990 and 2010. In 2011, an MI was one of the top five most expensive conditions during inpatient hospitalizations in the US, with a cost of about $11.5 billion for 612,000 hospital stays.
The three substrates of this enzyme are L-2-aminoadipate 6-semialdehyde (L-allysine), oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are (S)-α-aminoadipic acid, reduced NADH, and a proton. This enzyme can also use nicotinamide adenine dinucleotide phosphate as its cofactor. The enzyme participates in lysine biosynthesis and biodegradation.
==== Mechanical interlocking ==== The bioadhesives have the ability to diffuse and penetrate the pores and irregularities in the surface it is adhered to which forms a close interlock. This increases the contact area of the too surfaces and results in an increase in adhesive force. In bioinspired adhesive systems the application of Chitosan, was used as a bridging polymer in a 3D hydrogel network to perform topological wet adhesion. By creating strong physical bonds between synthetic materials, by creating non covalent bonds between H bonds. It was shown that Chitosan causes rapid cohesion 1000 J·m⁻² by 3 and 2000 J·m⁻² by 10 min. Chitosan diffuses and soaks which causes chitosan to move into the polyacrylamide mesh and weave themselves through. Chitosan penetrates deep as ~ 25 μm in tendon and skin after 10 min and 1h of compression respectively.
== Further reading == Mishra, NK; Agarwal, S; Raghava, GP (July 2010). "Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule". BMC Pharmacology. 10: 8. doi:10.1186/1471-2210-10-8. PMC 2912882. PMID 20637097.
Sources: en.wikipedia.org
=== Oligonucleotide biotinylation === Oligonucleotides are readily biotinylated in the course of oligonucleotide synthesis by the phosphoramidite method using commercial biotin phosphoramidite. Upon the standard deprotection, the conjugates obtained can be purified using reverse-phase or anion-exchange HPLC
Able to complete his School Certificate a year early, for which he was awarded seven credits, Sanger was able to spend most of his last year of school experimenting in the laboratory alongside his chemistry master, Geoffrey Ordish, who had originally studied at Cambridge University and been a researcher in the Cavendish Laboratory. Working with Ordish made a refreshing change from sitting and studying books and awakened Sanger's desire to pursue a scientific career. In 1935, prior to heading off to college, Sanger was sent to Schule Schloss Salem in southern Germany on an exchange program. The school placed a heavy emphasis on athletics, which caused Sanger to be much further ahead in the course material compared to the other students. He was shocked to learn that each day was started with readings from Hitler's Mein Kampf, followed by a Sieg Heil salute. In 1936 Sanger went to St John's College, Cambridge, to study natural sciences. His father had attended the same college. For Part I of his Tripos he took courses in physics, chemistry, biochemistry and mathematics but struggled with physics and mathematics. Many of the other students had studied more mathematics at school. In his second year he replaced physics with physiology. He took three years to obtain his Part I. For his Part II he studied biochemistry and obtained a 1st Class Honours. Biochemistry was a relatively new department founded by Gowland Hopkins with enthusiastic lecturers who included Malcolm Dixon, Joseph Needham and Ernest Baldwin.
==== India ==== The Department of Information Technology created the Indian Computer Emergency Response Team (CERT-In) in 2004 to thwart cyber attacks in India. That year, there were 23 reported cyber security breaches. In 2011, there were 13,301. That year, the government created a new subdivision, the National Critical Information Infrastructure Protection Centre (NCIIPC) to thwart attacks against energy, transport, banking, telecom, defense, space and other sensitive areas. The executive director of the Nuclear Power Corporation of India (NPCIL) stated in February 2013 that his company alone was forced to block up to ten targeted attacks a day. CERT-In was left to protect less critical sectors. A high-profile cyber attack on 12 July 2012 breached the email accounts of about 12,000 people, including those of officials from the Ministry of External Affairs, Ministry of Home Affairs, Defense Research and Development Organizations (DRDO), and the Indo-Tibetan Border Police (ITBP). A government-private sector plan being overseen by National Security Advisor (NSA) Shivshankar Menon began in October 2012, and intends to boost up India's cyber security capabilities in the light of a group of experts findings that India faces a 470,000 shortfall of such experts despite the country's reputation of being an IT and software powerhouse. In February 2013, Information Technology Secretary J. Satyanarayana stated that the NCIIPC was finalizing policies related to national cyber security that would focus on domestic security solutions, reducing exposure through foreign technology.
=== Ba–Bee === David Baker (b. 1962). American biochemist and computational biologist at the University of Washington, who studies methods to predict and design the three-dimensional structures of proteins. Nobel Prize in chemistry, 2024. Tania A. Baker (PhD 1988). American biochemist at MIT, who has studied transposons and enzymes that catalyse protein unfolding. Member Natl. Acad. Sci. USA. Clinton Ballou (1923–2021). American biochemist at UC Berkeley, whose research focused on the metabolism of carbohydrates and the structures of microbial cell walls. Member Natl. Acad. Sci. USA. Horace Barker (1907–2000). American biochemist and microbiologist at UC Berkeley. Member Natl. Acad. Sci. USA. David Bartel (PhD 1993). American biochemist at MIT, known for work on microRNA biology. Member Natl. Acad. Sci. USA. Bonnie Bassler (b. 1962). American molecular biologist at Princeton, known for studies of quorum sensing, and the idea that disruption of chemical signalling can be used as an antimicrobial therapy. Member Natl. Acad. Sci. USA. Philip A. Beachy (b. 1958). American biochemist at Stanford, known for studies to understand the molecular mechanisms behind the growth of multicellular embryos, especially the role of the Hedgehog signalling pathway. Member Natl. Acad. Sci. USA. Jon Beckwith (b. 1935). American microbiologist and geneticist at Harvard who made important contributions to the study of bacterial genetics. Member Natl. Acad. Sci. USA.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.